Researchers at Mount Sinai have achieved a significant breakthrough in treating hepatocellular carcinoma (HCC), the most ...

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

A new drug combination extends by 46% the time that liver cancer remains stable, according to an international clinical trial ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

When facing a cancer diagnosis, finding the most effective and innovative treatment options is crucial. Germany has emerged as a leading destination for advanced cancer treatments, offering ...

Navigantis Inc. recently announced the first successful neurovascular clinical cases performed with its Vasco interventional ro ...